To the best of our knowledge, this study is the first NMA to assess and compare the prophylactic benefits of individual GLP-1 receptor agonists and SGLT2 inhibitors on metastatic cancers with various origins. Here, SLC5A2 is linked to metastatic malignant neoplasm.